Expression of the catalytic and regulatory subunits of protein phosphatase type 2A may be differentially modulated during retinoic acid-induced granulocytic differentiation of HL-60 cells.
To elucidate the regulation of protein phosphatases types 1 (PP1) and 2A (PP2A) during all-trans retinoic acid (ATRA)-induced granulocytic differentiation of HL-60 cells, the phosphatase activity, proteins, and gene expressions of PP1 and PP2A were examined. Treatment with 1 microM ATRA caused an 85% decrease in the PP2A activity in extracts from HL-60 cells, while the PP1 activity was constant. This reduction in PP2A activity appeared to parallel phenotypic and functional changes of HL-60 cells induced by ATRA. Western blot analysis showed that the level of PP2A catalytic subunit (PP2A-C) decreased during the course of ATRA-induced differentiation, whereas expressions of A and B (M(r) 55,000) regulatory subunits of PP2A were relatively unaltered. Expressions of PP1 catalytic subunit isozymes (PP1 alpha, PP1 gamma, and PP1 delta) were not significantly affected by ATRA treatment. Northern blot analysis revealed that mRNA levels of PP2A-C beta and A alpha regulatory subunits were decreased following treatment with ATRA, while levels of PP2A-C alpha and B (M(r) 55,000) alpha regulatory subunit transcripts were relatively constant. Selective down regulation of PP2A-C beta preceded the granulocytic maturation induced by ATRA. Expressions of PP2A-C isoforms and A and B regulatory subunits may be differentially modulated during ATRA-induced granulocytic differentiation of HL-60 cells.
Nishikawa
M
M
2nd Department of Internal Medicine, Mie University School of Medicine, Japan.
Omay
S B
SB
Toyoda
H
H
Tawara
I
I
Shima
H
H
Nagao
M
M
Hemmings
B A
BA
Mumby
M C
MC
Deguchi
K
K
D015152:Blotting, Northern; D002454:Cell Differentiation / Q000187:drug effects; D003600:Cytosol / Q000201:enzymology; D015536:Down-Regulation; D004988:Ethers, Cyclic / Q000494:pharmacology; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases / Q000378:metabolism; D006098:Granulocytes / Q000187:drug effects / Q000201:enzymology* / Q000473:pathology; D006801:Humans; D015151:Immunoblotting; D015473:Leukemia, Promyelocytic, Acute / Q000201:enzymology* / Q000473:pathology; D008970:Molecular Weight; D009218:Myosins / Q000378:metabolism; D019319:Okadaic Acid; D010749:Phosphoprotein Phosphatases / Q000737:chemistry / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D014212:Tretinoin / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
D004988:Ethers, Cyclic; D012333:RNA, Messenger; D019319:Okadaic Acid; D014212:Tretinoin; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases; D010749:Phosphoprotein Phosphatases; D009218:Myosins